Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma
A Randomized Phase III Study of Docetaxel Versus Intercalated Erlotinib Docetaxel Combination Therapy in Patients With Relapsed EGFR (Epidermal Growth Factor Receptor) Wild Type, ALK(Anaplastic Lymphoma Kinase) Negative Non Squamous Cell Carcinoma. (NVALT 18 Study)
Sponsor: Dutch Society of Physicians for Pulmonology and Tuberculosis
Terminated
accrual to slow, target not achievable
Other Carcinoma, Non-small Cell Lung trials with similar outcome
This PHASE3 trial investigates Carcinoma, Non-small Cell Lung and is currently terminated or withdrawn. Dutch Society of Physicians for Pulmonology and Tuberculosis leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
May 2019 — Jan 2021 [monthly]
Terminated PHASE3
Status: Suspended → Terminated
▶ Show 6 earlier versions
-
Jun 2018 — May 2019 [monthly]
Suspended PHASE3
Status: Recruiting → Suspended
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE3
-
Aug 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dutch Society of Physicians for Pulmonology and Tuberculosis
- The Netherlands Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .